RTP Mobile Logo
Submitted by Anonymous on Tue, 09/09/2014 - 14:49

OVERVIEW OF ACTIVITY
Taken together, it is estimated that 156,420 new cases of lymphoma, multiple myeloma and leukemia will be identified in the United States in the year 2014, and 55,350 individuals will die of these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, with more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

This special audio highlights program of a CME satellite symposium held during the 2014 ASCO annual meeting uses one-on-one interviews with 2 leading investigators in lymphoma and 1 in multiple myeloma to discuss cases and questions submitted by meeting attendees. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

  • Compare and contrast completed and ongoing clinical trials evaluating novel investigational approaches for B-cell lymphomas and chronic lymphocytic leukemia (CLL), and prioritize clinical trial opportunities or expanded-access programs available to patients based on this information.
  • Appreciate the recent FDA approvals of ibrutinib, idelalisib and obinutuzumab, and discern how these agents can be appropriately integrated into clinical practice for patients with CLL.
  • Customize the selection of systemic therapy for patients with progressive mantle-cell lymphoma, recognizing the recent addition of new FDA-endorsed options for these patients.
  • Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage T-cell lymphomas, and ensure appropriate supportive care measures to minimize their associated side effects.
  • Compare and contrast the benefits and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic treatment for newly diagnosed active multiple myeloma (MM).
  • Customize the use of maintenance therapeutic approaches for MM in the post-transplant and nontransplant settings based on patient- and disease-related factors, including cytogenetic profile.
  • Consider available data on the selection, sequencing and/or combination of carfilzomib and pomalidomide in the management of relapsed/refractory MM.
  • Assess the ongoing clinical trials evaluating innovative investigational approaches for non-Hodgkin lymphomas and MM, and refer appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity contains both audio and print components. The participant should review the CME information, listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Friedberg — Advisory Committee and Other Uncompensated Activities: Genentech BioOncology. Dr Lonial — Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi. Dr Dreyling — Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Janssen Pharmaceuticals Inc, Pfizer Inc; Contracted Research: Celgene Corporation, Janssen Pharmaceuticals Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc; Speaking Honoraria: Celgene Corporation, Janssen Pharmaceuticals Inc, Pfizer Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Spectrum Pharmaceuticals Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: September 2014
Expiration date: September 2015